论文信息 - First-line erlotinib followed by second-line cisplatin-gemcitabine chemotherapy in advanced non-small-cell lung cancer: the TORCH randomized trial. - 字舞流文

First-line erlotinib followed by second-line cisplatin-gemcitabine chemotherapy in advanced non-small-cell lung cancer: the TORCH randomized trial.

A. Rossi | C. Gridelli | M. Tsao | G. Tortora | F. Ciardiello | G. da Cunha Santos | F. Morgillo | R. Wierzbicki | M. Di Maio | S. Siena | C. Gallo | N. Leighl | M. Piccirillo | V. Gebbia | A. Favaretto | R. Feld | C. Butts | A. Morabito | F. Perrone | P. Maione | S. Cinieri | M. Saieg | F. Riccardi | R. Felletti | G. Genestreti | G. Mancuso | Y. Alam | F. Cantile